NCT02788981: A Trial of Nanoparticle Albumin-Bound Paclitaxel (Nab-Paclitaxel, Abraxane) With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer

NCT02788981
Breast Cancer Type: Triple Negative
Hormone Mutations: GR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Endocrine (Hormone) Therapy, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Tumor must also be GR+
Exclusions: Patients with known brain metastases will be eligible, but conditions apply- see trial for details
https://ClinicalTrials.gov/show/NCT02788981

Comments are closed.

Up ↑